Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S.

Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Review.

PMID:
18506437
2.

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

Sanderson J, Ansari A, Marinaki T, Duley J.

Ann Clin Biochem. 2004 Jul;41(Pt 4):294-302. Review.

PMID:
15298741
3.

Review article: thiopurines in inflammatory bowel disease.

Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):715-29. Review.

4.

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.

Gearry RB, Barclay ML.

J Gastroenterol Hepatol. 2005 Aug;20(8):1149-57. Review.

PMID:
16048561
5.

Clinical pharmacogenomics of thiopurine S-methyltransferase.

Zhou S.

Curr Clin Pharmacol. 2006 Jan;1(1):119-28. Review.

PMID:
18666383
6.

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.

McLeod HL, Siva C.

Pharmacogenomics. 2002 Jan;3(1):89-98. Review.

PMID:
11966406
7.

Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.

Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR.

Dig Liver Dis. 2005 Apr;37(4):282-97. Review.

PMID:
15788214
8.
9.

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.

McLeod HL, Krynetski EY, Relling MV, Evans WE.

Leukemia. 2000 Apr;14(4):567-72. Review.

PMID:
10764140
10.

Recent advances in the pharmacogenomics of thiopurine methyltransferase.

Coulthard SA, Hall AG.

Pharmacogenomics J. 2001;1(4):254-61. Review.

PMID:
11908768
11.

Pharmacogenetics of thiopurines in inflammatory bowel disease.

Derijks LJ, Wong DR.

Curr Pharm Des. 2010;16(2):145-54. Review.

PMID:
20205660
12.

The thiopurines: an update.

Coulthard S, Hogarth L.

Invest New Drugs. 2005 Dec;23(6):523-32. Review.

PMID:
16267626
13.

The clinical impact of thiopurine methyltransferase polymorphisms on thiopurine treatment.

Coulthard SA, Matheson EC, Hall AG, Hogarth LA.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1385-91. Review.

PMID:
15571264
14.

Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.

Clunie GP, Lennard L.

Rheumatology (Oxford). 2004 Jan;43(1):13-8. Review.

PMID:
14566029
15.

Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, Relling MV, Evans WE.

Pharmacogenetics. 1996 Aug;6(4):279-90. Review.

PMID:
8873214
16.

Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.

Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X.

Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Review.

17.

Analytic aspects of monitoring therapy with thiopurine medications.

Armstrong VW, Shipkova M, von Ahsen N, Oellerich M.

Ther Drug Monit. 2004 Apr;26(2):220-6. Review.

PMID:
15228169
18.

Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.

Duley JA, Florin TH.

Ther Drug Monit. 2005 Oct;27(5):647-54. Review.

PMID:
16175140
19.

Pre-analytic and analytic sources of variations in thiopurine methyltransferase activity measurement in patients prescribed thiopurine-based drugs: A systematic review.

Loit E, Tricco AC, Tsouros S, Sears M, Ansari MT, Booth RA.

Clin Biochem. 2011 Jul;44(10-11):751-7. doi: 10.1016/j.clinbiochem.2011.03.022. Review.

PMID:
21402061
20.

Methylation pharmacogenetics: thiopurine methyltransferase as a model system.

Weinshilboum RM.

Xenobiotica. 1992 Sep-Oct;22(9-10):1055-71. Review.

PMID:
1441597
Items per page

Supplemental Content

Support Center